INCB3344

Catalog No.S8220 Batch:S822001

Print

Technical Data

Formula

C29H34F3N3O6
Molecular Weight 577.59 CAS No. 1262238-11-8
Solubility (25°C)* In vitro DMSO 100 mg/mL (173.13 mM)
Ethanol 100 mg/mL (173.13 mM)
Water Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
5%DMSO Corn oil
5.0mg/ml Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description INCB3344 is a potent, selective and orally bioavailable CCR2 antagonist with IC50 values of 5.1 nM (hCCR2) and 9.5 nM (mCCR2) in binding antagonism and 3.8 nM (hCCR2) and 7.8 nM (mCCR2) in antagonism of chemotaxis activity.
Targets
hCCR2 [1]
(in the MCP-1 binding assay)		 mCCR2 [1]
(in the MCP-1 binding assay)
5.1 nM 9.5 nM

Protocol (from reference)

Selleck's INCB3344 has been cited by 5 publications

Transcription factor EHF drives cholangiocarcinoma development through transcriptional activation of glioma-associated oncogene homolog 1 and chemokine CCL2 [ MedComm (2020), 2024, 5(5):e535] PubMed: 38741887
Disulfiram treatment suppresses antibody-producing reactions by inhibiting macrophage activation and B cell pyrimidine metabolism [ Commun Biol, 2024, 7(1):488] PubMed: 38649462
Disulfiram treatment suppresses antibody-producing reactions by inhibiting macrophage activation and B cell pyrimidine metabolism [ Commun Biol, 2024, 7(1):488] PubMed: 38649462
Elevated Mast Cell Abundance Is Associated with Enrichment of CCR2+ Cytotoxic T Cells and Favorable Prognosis in Lung Adenocarcinoma [ Cancer Res, 2023, 83(16):2690-2703] PubMed: 37249584
The CCL2-CCR2 axis contributes to acquired osimertinib resistance in lung cancer by upregulating Zeb1 expression [ Research Square, 2023, 10.21203/rs.3.rs-3674324/v1] PubMed: none

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.